Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems

18 Sep 2020 Evaluate

Brooks Laboratories has subscribed to 7963 equity shares at the face value of Rs 10 each of SteriBrooks Penems, amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The object of the said acquisition is to build a robust carbapenem business with integrated manufacturing capabilities.  

Brooks Laboratories has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials.

Brooks Laboratories Share Price

66.04 -1.86 (-2.74%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×